Clinical Trials

Accrual Status
Limit to SWOG Trials

1047 Results

Closed
Phase
Accrual
71%
Published
SWOG Clinical Trial Number
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
SWOG-9424

Phase II Trial of High Dose Tamoxifen Plus Cisplatin Chemotherapy in Metastatic Non-Small Cell Lung Cancer

Research Committee(s)
Lung Cancer
Activated
11-15-1994
Closed
12-01-1996
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9349
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9429
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9343
Closed
Phase
Accrual
49%
Published
SWOG Clinical Trial Number
SWOG-9219

A Phase II Evaluation of Interleukin-4 (IL-4) in Patients with Non-Hodgkin's Lymphoma

Research Committee(s)
Lymphoma
Activated
08-01-1994
Closed
08-01-1999
Closed
Phase
Accrual
39%
Published
SWOG Clinical Trial Number
SWOG-9350
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9212

Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma

Research Committee(s)
Gynecologic Cancer
Activated
05-15-1994
Closed
01-15-1997
Closed
Phase
Accrual
36%
SWOG Clinical Trial Number
SWOG-9428

Evaluation of DNA Ploidy and p53 in Patients Registered to SWOG-8794 and SWOG-9024, Ancillary

Research Committee(s)
Genitourinary Cancer
Activated
05-15-1994
Closed
12-01-1999
Closed
Phase
Accrual
89%
Published
Closed
Phase
Accrual
100%
Published
Closed
Phase
Published
Closed
Phase
Accrual
85%
Published
SWOG Clinical Trial Number
SWOG-9348
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-9208
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9339

Evaluation of Topotecan in Esophageal Carcinoma, Phase II

Research Committee(s)
Gastrointestinal Cancer
Activated
03-01-1994
Closed
12-15-1995
Closed
Phase
Accrual
90%
Published
SWOG Clinical Trial Number
SWOG-9228

Evaluation of Interleukin-4 (IL-4) in Disseminated Malignant Melanoma, Phase II

Research Committee(s)
Melanoma
Activated
03-01-1994
Closed
09-01-1995